Stock OJU1 ORAMED PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Oramed Pharmaceuticals Inc. Deutsche Boerse AG

Equities

OJU1

US68403P2039

Real-time Estimate Tradegate
Other stock markets
 03:37:42 2024-07-16 pm EDT 		5-day change 1st Jan Change
2.354 EUR +5.00% Intraday chart for Oramed Pharmaceuticals Inc. +0.04% +8.56%
Jun. 26 Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program MT
Jun. 26 Oramed Pharmaceuticals Inc. announces an Equity Buyback for $20 million worth of its shares. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program
MT
Oramed Pharmaceuticals : The Company’s Board of Directors authorized a stock buyback program to purchase up to $20,000,000
PU
Oramed Pharmaceuticals Inc. announces an Equity Buyback for $20 million worth of its shares.
CI
Oramed Pharmaceuticals Inc. authorizes a Buyback Plan.
CI
Oramed Pharmaceuticals : Received an additional payment from Scilex
PU
ORAMED PHARMACEUTICALS : 2023 ANNUAL REPORT
PU
Oramed Pharmaceuticals : PROXY STATEMENT OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON AUGUST 1, 2024
PU
Scilex Holding Signs Commitment Letter for $100 Million Financing; Shares Advance Premarket
MT
Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Chief Financial Officer, Effective as of June 18, 2024
CI
Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024
CI
Compugen Names David Silberman CFO
MT
Oramed Pharmaceuticals Inc. Announces Resignation of David Silberman as Chief Financial Officer, Effective July 12, 2024
CI
Oramed Pharmaceuticals Inc. Announces Resignation of David Silberman as Treasurer and Secretary, Effective July 12, 2024
CI
Oramed Pharmaceuticals : Management Change/Compensation - Form 8-K
PU
Oramed: Q1 Earnings Snapshot
AQ
Oramed Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Oramed Pharmaceuticals : Update on the receipt of payments for the Scilex transaction
PU
Oramed Pharmaceuticals : 13D-Nadav Kidron
PU
Oramed Pharmaceuticals : Update on the receipt of payments for the Scilex transaction
PU
Oramed Pharmaceuticals Inc. Appoints Yehuda Reznick as Director, Effective as of April 1, 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ORMP Stock
  4. OJU1 Stock
  5. News Oramed Pharmaceuticals Inc.